Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A β-haemolytic streptococci in 2002-2003 -: Results of the multinational GRASP Surveillance Program

被引：86

作者：

Beekmann, SE

Heilmann, KP

Richter, SS

García-De-Lomas, J

Doern, GV ^{[1
]}

机构：

[1] Roy J & Lucille A Carver Univ Iowa, Coll Med, Dept Pathol, Div Med Microbiol, Iowa City, IA 52242 USA

[2] Inst Valenciano Microbiol, Sch Med, Valencia, Spain

[3] Univ Hosp, Valencia, Spain

[4] Sch Med, Dept Microbiol, Valencia, Spain

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2005年 / 25卷 / 02期

关键词：

community-acquired respiratory tract infections; antimicrobial resistance; Streptococcus pneumoniae; group A streptococcus;

D O I：

10.1016/j.ijantimicag.2004.09.016

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

A multinational surveillance study, GRASP, was conducted between November 2002 and April 2003 with the aim of assessing rates of antimicrobial resistance among 2656 isolates of Streptococcus pneumoniae, 2486 isolates of group A beta-haemolytic streptococci, 1358 isolates of Haemophilus influenzae and 1047 of Moraxella catarrhalis from 20 countries in Europe, eastern Asia and southern Africa. Conspicuous differences between various countries were noted in the S. pneumoniae resistance rates observed for penicillin (0-79.2%) and erythromycin (4-66%), along with other antimicrobials. The percentage of MDR strains was above 25% in 8 of the 20 countries studied. Group A streptococcal macrolide resistance rates ranged from 0% to 35% by country, while rates of beta-lactamase production ranged from 0% to 39% for H. influenzae and 80-100% for M. catarrhalis. Antibiotic resistance in S. pneumoniae remains a significant problem world wide. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

引用

收藏

页码：148 / 156

页数：9

相关论文

共 19 条

[1] Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain [J].

Alós, JI ;

Aracil, B ;

Oteo, J ;

Gómez-Garcés, JL .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (02) :333-337

[2] Activity of telithromycin compared with seven other agents against 1039 Streptococcus pyogenes pediatric isolates from ten centers in central and eastern Europe [J].

Bozdogan, B ;

Appelbaum, PC ;

Kelly, LM ;

Hoellman, DB ;

Tambic-Andrasevic, A ;

Drukalska, L ;

Hryniewicz, W ;

Hupkova, H ;

Jacobs, MR ;

Kolman, J ;

Konkoly-Thege, M ;

Miciuleviciene, J ;

Pana, M ;

Setchanova, L ;

Trupl, J ;

Urbaskova, P .

CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (07) :741-745

[3] Activity of telithromycin and seven other agents against 1034 pediatric Streptococcus pneumoniae isolates from ten central and eastern European centers [J].

Bozdogan, B ;

Appelbaum, PC ;

Kelly, LM ;

Hoellman, DB ;

Tambic-Andrasevic, A ;

Drukalska, L ;

Hryniewicz, W ;

Hupkova, H ;

Jacobs, MR ;

Kolman, J ;

Konkoly-Thege, M ;

Miciuleviciene, J ;

Pana, M ;

Setchanova, L ;

Trupl, J ;

Urbaskova, P .

CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (07) :653-661

[4] Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000 [J].

Cantón, R ;

Loza, E ;

Morosini, MI ;

Baquero, F .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :9-24

[5] Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].

Chen, DK ;

McGeer, A ;

de Azavedo, JC ;

Low, DE .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239

[6] Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995 [J].

Doern, GV ;

Heilmann, KP ;

Huynh, HK ;

Rhomberg, PR ;

Coffman, SL ;

Brueggemann, AB .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1721-1729

[7] Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999 [J].

Hoban, DJ ;

Doern, GV ;

Fluit, AC ;

Roussel-Delvallez, M ;

Jones, RN .

CLINICAL INFECTIOUS DISEASES, 2001, 32 :S81-S93

[8] Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes:: SMART program 2001 data [J].

Hsueh, PR ;

Teng, LJ ;

Lee, CM ;

Huang, WK ;

Wu, TL ;

Wan, JH ;

Yang, D ;

Shyr, JM ;

Chuang, YC ;

Yan, JJ ;

Lu, JJ ;

Wu, JJ ;

Ko, WC ;

Chang, FY ;

Yang, YC ;

Lau, YJ ;

Liu, YC ;

Leu, HS ;

Liu, CY ;

Luh, KT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2152-2157

[9] In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae clinical isolates with different macrolide susceptibilities [J].

Ioannidou, S ;

Tassios, PT ;

Zachariadou, L ;

Salem, Z ;

Kanelopoulou, M ;

Kanavaki, S ;

Chronopoulou, G ;

Petropoulou, N ;

Foustoukou, M ;

Pangalis, A ;

Trikka-Graphakos, E ;

Papafraggas, E ;

Vatopoulos, AC .

CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (07) :704-707

[10] The Alexander Project 1998-2000:: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents [J].

Jacobs, MR ;

Felmingham, D ;

Appelbaum, PC ;

Grüneberg, RN .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (02) :229-246